HUAWEI eKit Unveils 20+ Cutting-Edge Products to Propel SME Digital and Intelligent Transformation
BARCELONA, Spain, March 12, 2025 /PRNewswire/ -- HUAWEI eKit made waves at Mobile World Congress (MWC) 2025, with an extraordinary product launch ceremony themed Explore New Horizons and Create a Better Future Together. The event featured over 20 distribution products designed for nine key sectors including offices, hospitality, and education. HUAWEI eKit aims to drive digital and intelligent transformation and foster efficient growth strategies through continuous product innovation for small and medium-sized enterprises (SMEs).
With SMEs increasingly seeking high-performing, intelligent products, HUAWEI eKit has set out to meet these demands, launching over 20 new products across various domains. The datacom domain saw HUAWEI eKit introduce the eKitEngine AP572 and AP673E for high-density Wi-Fi 7 coverage in both classrooms and large conference rooms. It also created the eKitEngine S310 switch with 2.5 Gbit/s speed, all-optical access, and PoE on all 48 ports, catering to medium-sized campuses such as schools and business hotels. In addition, Huawei unveiled their cost-effective AI firewall eKitEngine USG6000F-S. In the MiniFTTO domain, HUAWEI eKit developed a three-in-one optical Wi-Fi 7 access point (AP) – eKitOptix F700D, the next-generation Wi-Fi 7 AP – eKitOptix FG736, the efficient solid-state drive – eKitStor Xtreme 200E, and the portable storage device – eKitStor Shield 210, which is known for its exceptional performance and state-of-the-art protection features. The intelligent collaboration domain saw HUAWEI eKit launch the IdeaHub S3, which redefines high-end conference experiences with its professional-grade 4K camera, high-fidelity cinematic sound, and advanced AI capabilities. These products offer SMEs a wide range of scenario-based solutions and premium maintenance experiences, driving seamless digital transformation and accelerating business growth.
HUAWEI eKit has also upgraded its SME office network solution to better meet industry requirements. The new and improved solution now features a combination of high-density 2.5GE ports and Wi-Fi 7, in addition to the existing entry-level Wi-Fi 6 and cost-effective switch supporting both GE and 2.5GE. It is also capable of supporting 120 simultaneous HD video conferencing streams with zero lag, which provides SMEs with more advanced capabilities. Furthermore, the HUAWEI eKit app and SME Network Center (SNC) have introduced new features such as simplified troubleshooting 2.0 and streamlined expansion, improving overall maintenance efficiency for installers.
Moving forward, HUAWEI eKit will collaborate globally to drive innovation and explore trends in emerging communication technologies. With a focus on developing new products and scenario-based solutions, Huawei will continue to offer robust support for SMEs and pave the way for an intelligent future.
MWC Barcelona 2025 was held from March 3 to March 6 in Barcelona, Spain. During the event, Huawei showcased its latest products and solutions at stand 1H50 in Fira Gran Via Hall 1.
In 2025, commercial 5G-Advanced deployment will accelerate, and AI will help carriers reshape business, infrastructure, and O&M. Huawei is actively working with carriers and partners around the world to accelerate the transition towards an intelligent world.
For more information, please visit: https://carrier.huawei.com/en/events/mwc2025
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/huawei-ekit-unveils-20-cutting-edge-products-to-propel-sme-digital-and-intelligent-transformation-302399623.html
SOURCE HUAWEI
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
19 minutes ago
- New York Times
China Rejects Trump's Accusation That It Violated Trade Truce
China said on Monday that the United States had 'severely undermined' the trade truce the two countries reached last month, striking back against President Trump's accusations that it was violating the terms of their agreement. In a statement, China's Ministry of Commerce called Mr. Trump's attacks on social media last week 'baseless.' He had accused Beijing of failing to live up to its end of their trade deal, a 90-day rollback of tariffs and other trade barriers to give the two countries more time to negotiate and prevent an all-out trade war. China's commerce ministry said it had continued to honor its agreement responsibly and accused the United States of 'erroneous practices' by introducing a series of 'discriminatory restrictive measures.' These included restrictions on the sale of chip design software to China and barring American companies from using or financing artificial intelligence chips from the Chinese technology giant Huawei. It also criticized the Trump administration's announcement that it planned to 'aggressively revoke' the visas of Chinese students and that it would enhance scrutiny of all future applications from China, including Hong Kong. 'The U.S. side has unilaterally escalated new economic and trade frictions, exacerbating the uncertainty and instability of bilateral economic and trade relations,' the ministry wrote in its statement. 'Instead of reflecting on its own actions, it has turned the blame onto China.' China said it would take measures to 'safeguard its legitimate rights and interests' if the United States continued to harm Chinese interests. The growing confrontation over the fragile trade truce between the world's two largest economies has raised questions about whether they can strike a permanent accord within the 90-day deadline. The United States has grown increasingly concerned about access to rare earth magnets, which are crucial for producing cars, semiconductors, aircraft and other vital items. China maintains a near monopoly on the production of rare earth metals. American companies' ability to keep factories running could be in jeopardy without a sufficient supply of those magnets. Jamieson Greer, the U.S. trade representative who negotiated the deal along with Treasury Secretary Scott Bessent, said during a Friday appearance on CNBC that China was 'slow-rolling their compliance' and that the flow of some critical minerals has not returned to levels that American officials were expecting. The agreement, announced on May 12, offered a temporary reprieve to the escalating trade tensions between the two largest economies. The United States had pushed tariffs on Chinese imports to 145 percent and China responded by raising import duties on American products to 125 percent. Under the truce, the United States agreed to lower its tariffs to 30 percent, while China cut its import tax to 10 percent for 90 days. Amy Chang Chien contributed reporting from Taipei.
Yahoo
3 hours ago
- Yahoo
China says US has 'severely violated' tariffs truce
China says the US has "severely violated" their trade truce and will take strong measures to defend its interests. China's Ministry of Commerce said Washington has "seriously undermined" the agreement reached during talks in Geneva last month, when both countries lowered tariffs on goods imported from each other. The spokesperson added that US actions have also severely violated the consensus reached during a phone call in January between China's leader Xi Jinping and President Donald Trump. The comments come after comments by Trump on Friday that China had "totally violated its agreement with us". The US President did not give details but Trade Representative Jamieson Greer later said China had not been removing non-tariff barriers as agreed under the deal. Under the trade truce struck in May at a meeting in Geneva, the US lowered tariffs imposed on goods from China from 145% to 30%. China's retaliatory tariffs on US goods dropped from 125% to 10%. On Monday, Beijing said US violations of the agreement included stopping sales of computer chip design software to Chinese companies, warning against using chips made by Chinese tech giant Huawei, and cancelling visas for Chinese students. What tariffs has Trump announced and why? Trump tariffs get to stay in place for now. What happens next? Meanwhile two top White House officials suggested on Sunday that Trump and Xi could hold talks soon. Treasury Secretary Bessent told CBS News, the BBC's US news partner, that details of the trade will be "ironed out" once Xi and Trump speak, but he did not say exactly when that conversation is expected to happen. National Economic Council Director Kevin Hassett told ABC News that the two leaders are expected to talk this week and "both sides have expressed a willingness to talk". "The bottom line is that we've got to be ready in case things don't happen the way we want," Hassett said of the expected talks. Last week, Trump announced the US would double its current tariffs on steel and aluminium from 25% to 50%, starting on Wednesday. Speaking at a rally in Pittsburgh, Pennsylvania on Friday, Trump said the move would help boost the local steel industry and national supply, while reducing reliance on China.
Yahoo
7 hours ago
- Yahoo
CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
SHANGHAI, June 1, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: a company focused on developing innovative CAR T-cell therapies, announces that the results of the pivotal Phase II clinical trial in China (CT041-ST-01, NCT04581473) investigating satricabtagene autoleucel ("satri-cel", CT041) (a Claudin18.2-specific autologous CAR T-cell product candidate) in patients with Claudin18.2-positive, advanced gastric/gastroesophageal junction cancer refractory to at least two prior lines of treatment, have been published in The Lancet and were orally presented at the 2025 ASCO Annual Meeting. Further details have been posted on the corporate website The article in The Lancet was titled "Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial". Full article available at: The oral presentation at the 2025 ASCO Annual Meeting (Abstract 4003) was titled "Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01)". Professor Lin Shen from Beijing Cancer Hospital, the principal investigator of this study, said, "The CT041-ST-01 trial represents the world's first randomized controlled clinical study of CAR-T cell therapy for solid tumors. In patients with heavily pretreated, advanced gastric/gastroesophageal junction cancer who have extremely limited treatment options and poor prognosis, satri-cel has demonstrated breakthrough efficacy with significant clinical benefits, including much improved progression-free survival (PFS), overall survival (OS), and tumor response rates. This brings new hope to patients with otherwise medically untreatable conditions. We are further exploring satri-cel's potential in adjuvant settings and as first-line sequential therapies, aiming to intervene earlier in the disease course, extend patients' survival, and ultimately pursue potential cures." Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, "We are honored that the CT041-ST-01 study results were published in The Lancet—a premier, global medical journal—and presented at the 2025 ASCO Annual Meeting. The positive result of this randomized controlled trial marks a major milestone in solid tumor CAR-T therapy. These achievements are a testament to the whole research team's years of dedication, and we extend our deepest gratitude to patients and their families for their trust and participation. This year, satri-cel has been granted Breakthrough Therapy Designation and Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy. We plan to submit a New Drug Application (NDA) for satri-cel to the NMPA this month and anticipate its approval as the world's first commercially available CAR-T product for solid tumors, bringing benefits to patients." About Satri-cel Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors with a primary focus on G/GEJA and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase Ib clinical trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595). Satri-cel has been granted Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in May 2025. Satri-cel has been granted Breakthrough Therapy Designation by the CDE of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in March 2025. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA in September 2020 for the treatment of G/GEJA. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgen For more information, please visit View original content to download multimedia: SOURCE CARsgen Therapeutics
